Topics

Companies Related to "UPLAT Placebo Thrombocytopenia" [Most Relevant Company Matches] [Advanced Search Results] RSS

03:21 EST 9th December 2019 | BioPortfolio

Here are the most relevant search results for "UPLAT Placebo Thrombocytopenia" found in our extensive corporate database of over 50,000 company records.

Showing "UPLAT Placebo Thrombocytopenia" Companies, all 24

Relevant

Privia

A clinical trial is a research study. Research studies are used to decide how treatments work and how safe they are. While in a study, a person may receive either an investigational drug, a marketed drug, a placebo, or a combination of these. An investigational drug is one that is nor approved by the Food and Drug Administration, a marketed drug is FDA approved and a placebo is like a "sugar pill"...


Adeona Pharmaceuticals, Inc.

Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration. Trimesta (estriol) ...

Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...


Ipsen Biopharmaceuticals, Inc.

*MAS responders week 4: 74% to Dysport® 500 units, 79% to Dysport® 1000 units and 23% to placebo

Veralox Therapeutics

VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of thrombosis and type 1 diabetes. The company’s lead candidate, VLX-1005, will be developed initially to treat patients with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). Second generation therapeutic products are under development for ty...

Agennix

Agennix is a privately held biotechnology company whose lead molecule, Talactoferrin Alfa (talactoferrin; TLF), is an immunomodulatory protein. Agennix is currently preparing to initiate Phase III development of oral talactoferrin for cancer, and topical talactoferrin gel for wound healing.Liquid talactoferrin is an oral anti-cancer drug that has shown activity both as monotherapy and in combinati...

Probably Relevant

Dr. Kim-Chi Vu

One of only a handful of female plastic surgeons in Portland, Dr. Kim-Chi Vu attended the University of Portland as an undergraduate and graduated from medical school at the Oregon Health Sciences University, where she also completed her surgical residency. Dr. Vu certified by the American Board of Plastic Surgery, specializes in not only cosmetic and reconstructions, but also in hand trauma surge...

Neumedicines Inc.

Neumedicines Inc. is developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology and immunology. The company’s lead product candidate is HemaMax™ (recombinant human interleukin-12, or rHuIL-12), which functions by targeting multiple pathways of hematopoiesis and innate immunity. HemaMaxâ„...

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...

Rigel Pharmaceuticals

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellu...

aTyr Pharma, Inc.

aTyr Pharma engages in the generation of innovative therapeutics based on a new class of naturally occurring human proteins. These proteins, called resectins, modulate extracellular signaling pathways in a variety of biological processes. Resectins, previously overlooked by genomic efforts due to their hidden intra-protein location in ancient aminoacyl tRNA synthetase genes, have recently been d...

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....

Ironshore Pharmaceuticals Inc.

The effectiveness of JORNAY PM was established in two separate Pivotal Phase III, multicenter, randomized, double-blind, placebo-controlled studies conducted in a total of 278 pediatric patients aged 6 to 12 years with a diagnosis of ADHD per DSM-5 criteria. In addition to the traditional scales that assess efficacy in ADHD clinical trials such as the Swan...

Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

Prescription Dispensing Laboratories

Prescription Dispensing Laboratories announces a major discovery related to the use of calcium channel blockers for the noninvasive, topically applied transdermal treatment of Peyronie's Disease, Dupuytren's Contracture, Plantar Fibromatosis and related connective tissue disorders worldwide patents are pending). Accept no imitations. Transdermal verapamil is available only from PDLABS.A comparison...

DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a comm...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development ...

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Favrille

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response...

Opsona Therapeutics Ltd

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

LifeWave Ltd

Incorporated in 2000, LifeWave Ltd. is a premier provider of innovative medical device in the field of Advanced Wound Management. The Company has developed an extensively researched and clinically-validated product that represents a truly novel approach in addressing the critical medical issue of chronic wounds care. LifeWave is currently focused on introducing its product to global markets. Chron...

Nutrition 21

Leveraging its biotechnology heritage, Nutrition 21 is pioneering an effort to use patented technology, pharmaceutical research and strategic marketing and distribution partnerships to build its position in therapeutic markets. The Company is targeting specific disease states and age related health care concerns through its Chromax®, Diachrome®, Iceland Health®, and Selenomax® brands. The dis...

Possibly Relevant

Nabi Biopharmaceuticals

NABI Biopharmaceuticals are a biopharmaceutical company focused on the development of products that address unmet medical needs in the areas of nicotine addiction and infectious disease. We leverage our experience and knowledge in powering the human immune system to target serious medical conditions in these areas. Our lead products in development are NicVAX® [ Nicotine Conjugate Vaccine ], an in...


More From BioPortfolio on "UPLAT Placebo Thrombocytopenia"

Quick Search

Corporate Database Quicklinks